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Delayed melatonin administration promotes neuronal survival,
neurogenesis and motor recovery, and attenuates hyperactivity
and anxiety after mild focal cerebral ischemia in mice
Abstract
Melatonin is a potent antioxidant with neuroprotective activity in animal models of ischemic stroke,
which based on its lack of serious toxicity has raised hopes that it might be used for human stroke
treatment in the future. This study investigated how subacute delivery of melatonin, starting at 24 hr
after stroke onset, and continuing for 29 days (4 mg/kg/day; via drinking water), influences neuronal
survival, endogenous neurogenesis, motor recovery and locomotor activity in C57Bl6/j mice submitted
to 30-min middle cerebral artery occlusion. Histologic studies showed that melatonin improved neuronal
survival and enhanced neurogenesis, even when applied 1 day after stroke. Cell survival was associated
with a long-lasting improvement of motor and coordination deficits, evaluated by the grip strength and
RotaRod tests, as well as with attenuation of hyperactivity and anxiety of the animals as revealed in
open field tests. The robust functional neurologic improvements encourage proof-of-concept studies
with melatonin in human stroke patients.
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Abstract Melatonin is a potent antioxidant with neuroprotective activity in animal 
models of ischemic stroke, which based on its lack of serious toxicity has raised 
hopes that it might be used for human stroke treatment in the future. This study 
aimed to investigate how subacute delivery of melatonin, starting at 24 hours after 
stroke onset, continued until 30 days (4 mg/kg/day; via drinking water), influences 
neuronal survival, endogenous neurogenesis, motor recovery and locomotor activity 
in C57Bl6/j mice submitted to 30 min middle cerebral artery occlusion. Histological 
studies showed that melatonin improved neuronal survival and enhanced 
neurogenesis, even when applied one day after stroke. Cell survival was associated 
with a long-lasting improvement of motor and coordination deficits, evaluated by grip 
strength and RotaRod tests, as well as with attenuation of animal hyperactivity and 
anxiety revealed in open field tests. The robust functional neurological improvements 
encourage proof-of-concept studies with melatonin in human stroke patients. 
Key-words: Ischemic stroke, free radical scavenger, motor coordination, locomotor 
activity, anxiety. 
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Introduction 
Neuroprotection has made limited progress in ischemic stroke in humans recently. As 
such, more than sixty compounds known to be protective in animal models of focal 
cerebral ischemia were tested in stroke patients in the past decades, out of which not 
a single compound turned out to be beneficial under clinical conditions [1]. The 
recent failure of the SAINT-II study is just the latest example in this long series of 
unsuccessful trials [2,3]. 
In view of previous study failures, there is a clear need to reflect our strategies 
in drug development. As such, it has been pointed out that (a) the window of 
opportunity of a candidate compound [4], (b) its potential side effects [4], (c) its ability 
to pass the blood-brain barrier [5,6], as well as (d) its utility as add-on treatment to 
thrombolytics [7-9] should carefully be scrutinized in preparation for neuroprotection 
trials. 
We and others have shown previously that the neurohormone melatonin, 
which based on its small molecular size and lipophilicity possesses excellent blood-
brain barrier permeability and which has minimal side effects in humans (for review 
see [10,11]), reduces brain injury in mouse [12-15] and rat [16-19] models of 
ischemic stroke, being particularly suitable as add-on treatment to thrombolytic drugs 
[13,15].  
In earlier studies, melatonin was shown to be protective when delivered after 
[12-19] as well as prophylactically up to nine weeks prior [12,14] to stroke. In 
molecular biological studies, cellular signalling mechanisms underlying melatonin’s 
neuroprotective actions were identified [12-15,20,21].  
While previous studies focussed on structural effects of melatonin during the 
few days after stroke, its functional neurological effects still had to be assessed with 
more detail. In the present studies, we examined effects of melatonin delivered with 
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24 hours delay, on neuronal survival, endogenous neurogenesis and functional 
neurological recovery in a model of mild focal cerebral ischemia. 
 
Materials and methods 
Animals 
Experiments were carried out with government approval (Kantonales Veterinäramt 
Zürich, ZH169/2005) according to local guidelines for the care and use of laboratory 
animals. Adult male C57Bl/6 mice weighing 23-25 g were attributed to three groups, 
that either remained untreated or were treated with vehicle (100 µl ethanol, dissolved 
in 300 ml drinking water) or melatonin (0.025 mg/ml; dissolved in 100 µl ethanol/ 300 
ml drinking water) starting at 24 hours after reperfusion onset over the subsequent 29 
days (n = 7 animals / group). The concentration of 0.025 mg/ml melatonin was 
chosen based on our observation that adult mice consume approximately 4 ml 
drinking water each day, in order to ensure a daily intake of ~4 mg/kg b.w. of 
melatonin per animal [12,14]. Drinking bottles were wrapped in aluminum foil in order 
to prevent light-induced degradation of melatonin. In addition to the oral route of drug 
administration, melatonin-treated mice received a single i.p. bolus injection of 4 
mg/kg b.w. melatonin at 24 hours after reperfusion onset. Vehicle treated animals 
received an injection of carrier fluid. Animals were held under a constant 12:12 hr 
light-darkness regimen (lights on daily at 6:30 a.m.). 
 
Animal surgery 
Animals were anesthetized with 1% halothane (30% O2, remainder N2O). Rectal 
temperature was maintained between 36.5 and 37.0°C using a feedback-controlled 
heating system. During the experiments, cerebral blood flow was measured by laser 
Doppler flow (LDF) measurements using a flexible 0.5 mm fiber optic probe 
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(Perimed, Stockholm, Sweden), which was attached to the intact skull overlying the 
middle cerebral artery (MCA) territory (2 mm posterior / 6 mm lateral from bregma). 
LDF changes were monitored up to 30 min after the onset of reperfusion. Focal 
ischemia was induced using an intraluminal filament technique [22-24]. A midline 
neck incision was made, and the left common and external carotid arteries were 
isolated and ligated. A microvascular clip (FE691, Aesculap, Tuttlingen, Germany) 
was temporarily placed on the internal carotid artery. A 8-0 nylon monofilament 
(Ethilon; Ethicon, Norderstedt, Germany) coated with silicon resin (Xantopren, Bayer 
Dental, Osaka, Japan; diameter of the coated thread: 180-200 µm) was introduced 
through a small incision into the common carotid artery and advanced 9 mm distal to 
the carotid bifurcation for MCA occlusion. Thirty minutes after induction of ischemia, 
reperfusion was initiated by withdrawal of the monofilament. Anesthesia was 
discontinued and animals were placed back into their cages.  
 
Cell proliferation studies, animal sacrifice and analysis of brain damage 
Twenty-nine days after MCA occlusion, animals were treated with three i.p. bolus 
injections of 5'-bromo-2'-deoxyuridine (BrdU) (50 mg/kg; Sigma, Deisenhofen, 
Germany), separated by 4 hrs, for the identification of proliferating endogenous 
neural precursor cells. One day later, animals were deeply anesthetized (1% 
halothane) and decapitated. Brains were removed and frozen on dry ice. 
Subsequently, brains were cut on a cryostat into 18 µm coronal sections, which were 
used for cresyl violet staining according standard protocols [23] and BrdU 
immunohistochemistry. In cresyl violet-stained brain sections, the density of surviving 
medium-sized neurons was evaluated in nine random regions of interest (ROI) of the 
striatum (done by Ü.K.), separated by 1 mm (size of sampled areas: 62,500 µm2 
each) [25]. For all ROI, mean values were calculated. 
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Immunohistochemistry for BrdU 
Brain sections were fixed with 4% paraformaldehyde in 0.1 M PBS for 1 h at room 
temperature, and incubated in 2 M HCl at 37 °C for 1 h. Sections were then 
immersed in rat monoclonal anti-BrdU (1:200; Accurate Chemical, Westbury, NY, 
USA) antibody. Following rinsing in 0.1 M PBS, staining was revealed with a 
rhodamine-conjugated goat anti-rat antibody (Jackson ImmunoResearch, West 
Grove, PA, USA) were used (diluted 1:200). Brain sections were evaluated under a 
fluorescence microscope. Expression levels were analyzed in a blinded manner 
(done by A.F.) by counting immunopositive cells in nine random ROI of the striatum, 
separated by 1 mm (size of areas: 62,500 µm2 each). For all ROI, mean values were 
again calculated. 
 
Evaluation of motor recovery and behavioral deficits 
For assessment of functional neurological deficits, grip strength, RotaRod and open 
field tests were used.  
Grip strength test. The grip strength test consists of a spring balance coupled with a 
Newtonmeter (Medio-Line Spring Scale, metric, 300 g, Pesola AG, Switzerland) that 
is attached to a tringular steel wire, which the animal instinctively grasps. When 
pulled by the tail, the animal exerts force on the steel wire [26]. Grip strength was 
evaluated at right paretic forepaw of mice submitted to left-sided MCA occlusion, the 
left non-paretic forepaw being wrapped with adhesive tape. Grip strength was 
evaluated five times on occasion of each test, which took place on the day prior to 
stroke and on days 7 and 30 after ischemia. For all five measurements, mean values 
were calculated. 
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RotaRod test. The RotaRod consists of a rotating drum with a speed accelerating 
from 4 to 40 rpm (Ugo Basile, model 47600, Comerio, Italy; ref. [27]). Maximum 
speed is reached after 245 seconds, and the time at which the animal drops off the 
drum is evaluated (maximum testing time: 300 seconds). Measurements were 
repeated five times on occasion of each examination, which were scheduled on the 
same days as grip strength tests. For all measurements, mean values were 
determined. 
Open field test. This test was used to detect spontaneous locomotor activity and 
exploration behavior. The open field consists of a round arena (diameter: 150 cm) 
covered by a white plastic floor, surrounded by a 35 cm high sidewall made of white 
polypropylene. The arena was divided into 3 sections, including an outer home zone 
(17.73% of diameter, close to the wall), an intermediate transition zone (32.27% of 
diameter) and an inner exploration zone (50% of diameter, the center of the arena). 
Each mouse was released near the wall and observed for 10 min. Animal paths were 
tracked with an electronic imaging system (ETHOVISION 3, Noldus Information 
Technology, Wageningen, The Netherlands), acquiring data at a frequency of 4.2 Hz 
with a spatial resolution of 576x768 pixels. Raw data were transferred to the 
WINTRACK 2.4 software for offline analysis [28]. To characterize animal activity, 
resting, scanning and progressing times were evaluated. To determine measures of 
exploratory behavior and anxiety, the percentage time spent in each of the three 
zones and the number of zone visits were also assessed. Tests were conducted on 
two consecutive days prior to stroke, on days 5 and 6, as well as on days 28 and 29 
after stroke, resulting in a total observation time of 20 min per animal for each time 
point [29]. 
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Statistics 
All data are given as mean ± SD. Differences between groups were compared by 
oneway ANOVA (comparisons between ≥3 groups), two-tailed t-tests (comparisons 
between 2 groups) and repeated measurements ANOVA (comparisons with ≥2 time 
points). P values < 0.05 were considered to indicate statistical significance. 
 
Results 
 
Melatonin promotes neuronal survival and endogenous neurogenesis 
Laser Doppler flowmetry. To ensure the reproducibility of ischemias, LDF recordings 
were performed above the core of the MCA territory. As previously shown [22, 23,30], 
MCA occlusion resulted in a decrease of LDF values to ∼15% of pre-ischemic control 
values (Fig. 1A). After reperfusion, LDF values rapidly normalized (Fig. 1A). No 
differences were found between non-treated, vehicle treated and melatonin treated 
mice (Fig. 1A).  
Neuronal survival. To investigate melatonin’s effects on neuronal survival, cresyl 
violet stainings were analyzed. As in earlier studies [24,25], 30 min MCA occlusion 
resulted in disseminated neuronal injury in the striatum, but not in the overlying cortex 
(Fig. 1B). Interestingly, the number of surviving medium-sized neurons in the 
striatum, assessed by cresyl violet, was significantly higher in animals treated with 
melatonin than in untreated or vehicle treated mice (Fig. 1B), indicating that 
melatonin exerted structural rescue effects despite the fact that it was applied with 24 
hours delay. 
Endogenous neurogenesis. To characterize neural precursor cell proliferation in the 
ischemic brain, BrdU incorporation was examined by immunohistochemistry. BrdU 
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stainings revealed that melatonin stimulated cell proliferation in ischemic brain, the 
number of BrdU+ cells being significantly increased by melatonin (Fig. 1C).  
  
Melatonin enhances recovery of motor coordination 
To elucidate how melatonin influences motor recovery, grip strength and RotaRod 
tests were evaluated. Grip strength tests performed at seven days after stroke 
revealed a mild paresis of the right forelimb that was associated with more 
pronounced coordination deficits in RotaRod tests in case of non-treated and vehicle 
treated mice (Fig. 2). Melatonin significantly enhanced the animals’ motor 
coordination, RotaRod performance being reversed almost to levels of non-ischemic 
mice (Fig. 2). The motor improvements persisted at 30 days after stroke (Fig. 2), 
indicating a sustained effect of melatonin on functional neurological recovery.   
 
Melatonin antagonizes animal hyperactivity and anxiety 
To characterize how melatonin affects spontaneous locomotor activity, open field 
tests were evaluated. Reduced resting times were observed in vehicle treated mice 
at 6 days following stroke that together with increased progressing times and more 
frequent zone visits indicated animal hyperactivity (Fig. 3). Melatonin attenuated this 
hyperactive behavior (Fig. 3).  
The increased locomotor activity disappeared at 29 days after stroke (Fig. 3). 
At that time, an increased anxiety, indicated by an increased preference to spend 
time in the home zone, became evident in vehicle treated animals (Fig. 3). Melatonin 
reversed this anxious phenotype (Fig. 3). 
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Discussion 
The preparation of clinical trials with neuroprotective compounds requires careful 
animal studies, in which clinically-relevant structural and functional improvements are 
shown that persist in the post-acute stroke phase. This requires histological as well 
as behavioral neurological studies, in which drug effects are assessed both in the 
acute and post-acute stroke phase. We herein examined effects of melatonin, 
administered starting at 24 hours after stroke, on functional neurological recovery in a 
model of mild focal cerebral ischemia, i.e., 30 min MCA occlusion. By histological 
analysis of brain injury and cell proliferation, as well as by assessment of motor 
function, coordination and locomotor activity, we show that melatonin (a) exerts 
neuroprotective activity after mild focal cerebral ischemia, even when delivered with 
24 hours delay, (b) stimulates endogenous neurogenesis, (c) promotes the recovery 
of motor and coordination deficits and (d) attenuates post-ischemic hyperactivity and 
anxiety.  
The 30 min MCA occlusion model we used exhibits very low mortality (in our 
hands less than 10%) and induces only mild motor deficits [22,31]. This was 
important with respect to the coordination and locomotor tests, in which hemiparesis 
would invariably have resulted in pathological findings that would have made data 
interpretation impossible. We have shown previously that 30 min MCA occlusion 
induces disseminate neuronal injury in the mouse striatum, which evolves over 
approximately three days [24]. Unlike in longer ischemias, overt brain infarcts are not 
observed under such conditions [24]. We were surprised that melatonin had a 
beneficial effect on neuronal survival, despite the fact that the antioxidant was 
delivered not before 24 hours after stroke. Our data support earlier conclusions that 
melatonin is indeed a highly potent neuroprotectant.  
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The time window, in which drugs are able to rescue brain tissue, is a critical 
factor in drug development. As such, thrombolytic compounds are efficacious only 
when applied within 3 hours, possibly up to 4.5 hours after stroke onset in human 
patients [32,33]. Under clinical conditions, a short time window precludes broader 
clinical application, limitating the number of patients that may receive a treatment. In 
case of thrombolytics, less than 10% of patients are currently eligible for 
recanalization therapies, even in large University hospitals. That melatonin was able 
to prevent ischemic injury even when delivered one day after stroke is highly 
promising with respect to future clinical trials. It raises hope that more patients might 
take benefit from this drug. Until now, melatonin had never been delivered more than 
two hours after stroke in animal studies [34]. 
In addition to its neuroprotective activity, melatonin enhanced cell proliferation in 
the ischemic brain, indicating that the antioxidant stimulated endogenous 
neurogenesis. BrdU is incorporated into newly synthetized DNA in the S phase of the 
cell cycle. As such, BrdU incorporation is not specific for neural progenitor cells. In 
fact, BrdU incorporation also takes place in inflammatory cells, which similarly to 
neural progenitors show proliferative activity [35]. In view that melatonin exerts a 
powerful anti-inflammatory action in the stroke brain [10,11], the incorporation of 
BrdU in inflammatory cells is rather a theoretical explanation for the enhanced cell 
proliferation. In the literature different observations exist regarding melatonin’s effects 
on neurogenesis. As such, in vivo studies using rat pups have shown that melatonin 
increases the proliferation of neural progenitor cells in the dentate gyrus [36]. In vitro 
studies, on the other hand, demonstrated that pharmacological doses of melatonin 
suppress epidermal growth factor (EGF)-induced neural progenitor cell proliferation in 
a concentration-dependent manner, most likely by stimulating the neural 
differentiation of the cells [37], putatively as a consequence of melatonin’s antioxidant 
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effects. We have not analysed the differentiation of progenitor cells in our present 
experiments. Future studies are necessary to elucidate this issue. 
In behavioural tests we for the first time show that melatonin promotes the 
recovery of motor coordination and attenuates the hyperactivity and anxiety of 
ischemic mice. In our studies, only a mild paresis of the right forelimb was noticed in 
ischemic mice after 30 min MCA occlusion, which is in line with findings from another 
group using SV129 mice [31]. Despite the mild motor weakness, the ischemic 
animals had significant deficits in the RotaRod test, which were almost completely 
reversed by melatonin. It is noteworthy that melatonin not only influenced motor 
dysfunctions in a very robust way, but also had a stabilizing effect on the animals’ 
hyperactivity and anxiety. Hyperactivity and anxiety are well-known features during 
stroke recovery, which have previously been described after mild focal cerebral 
ischemia in SV129 mice [31], where they were interpreted as correlate of human 
post-stroke depression. Although it remains to be shown whether the increased 
locomotor activity and anxiety in C57Bl6 mice indeed reflects a depression-like state, 
the stabilizing psychomotor effects of melatonin are encouraging. Psychomotor side 
effects are a frequent reason for failure in clinical pharmacological trials. Future 
studies should more carefully consider locomotor tests when characterizing actions of 
neuroprotective drugs. 
In conclusion, our study provides evidence that melatonin induces functionally 
relevant neurological improvements in stroke mice, furthermore exerting a delayed 
neuroprotective action and also stimulating endogenous neurogenesis. In view of the 
unique advantage that melatonin is already administered under clinical conditions for 
other purposes (e.g., for treatment of circadian disorders), considering that this anti-
oxidant has, if at all, little side effects [10,11], future studies should more stringently 
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evaluate time windows and dose-response relationships of melatonin. With such 
information, proof-of-concept studies in human patients should be faced.  
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Legends to Figures: 
Fig. 1. Melatonin, delivered starting at 24 hours following 30 min MCA occlusion 
promotes neuronal survival and stimulates endogenous neurogenesis. LDF during 
and immediately after ischemia (A), percentage of surviving neurons in the ischemic 
striatum, assessed by cresyl violet staining (B) and cell proliferation assessed by 
BrdU immunohistohemistry (C) in non-treated, vehicle treated and melatonin treated 
mice. Note that LDF does not differ between groups (A). In (C), representative BrdU 
stainings are also shown, exhibiting BrdU+ cells in the left-sided ischemic, but not 
right-sided non-ischemic striatum (Str). Data are means ± SD (n = 7 animals/ group). 
*p< 0.05 compared with non-treated animals/ †p< 0.05 compared with vehicle treated 
animals. CC, corpus callosum; SVZ, subventricular zone. Bar, 1 mm. 
 
Fig. 2. Melatonin promotes motor recovery in animals submitted to 30 min MCA 
occlusion. Grip strength and RotaRod tests in mice prior to ischemia, and at 7 and 30 
days post-stroke. Note the mild paresis of the right forelimb, revealed by grip strength 
tests, as well as the more pronounced coordination deficit in RotaRod tests that is 
almost completely reversed by melatonin. Data are means ± SD (n = 7 animals/ 
group). Data were analyzed by repeated measurement ANOVA, for which condition x 
time interaction effects are shown, followed by t-tests. *p< 0.05/ **p< 0.01 compared 
with baseline; †p< 0.05/ ††p< 0.01 compared with vehicle treated ischemic mice. 
 
Fig. 3. Melatonin attenuates post-ischemic hyperactivity and anxiety. Resting, 
scanning and progressing times, as well as zone preferences of animals submitted to 
30 min MCA occlusion. Note the reversible animal hyperactivity at 6 days after 
stroke, reflected by reduced resting times as well as by increased visits to the home, 
transition and exploration zones, which is more pronounced in vehicle than in 
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melatonin treated mice. Also note the enhanced anxiety at 29 days post-stroke, 
reflected by an increased preference to spend time in the home zone, in vehicle 
treated animals, that is reversed by melatonin. Data are means ± SD (n = 7 animals/ 
group). Data were analyzed by repeated measurement ANOVA, for which condition x 
time interaction effects are shown, followed by t-tests. *p< 0.05/ **p< 0.01 compared 
with baseline; †p< 0.05/ ††p< 0.01 compared with vehicle treated ischemic mice. 
 
